Sertraline safety in adolescents experiencing a depressive episode during first 3 weeks: added anxiolytic matters more than CYP2C19 polymorphisms
Frontiers in Pharmacology · 02.03.2026 · 17
DOI: 10.3389/fphar.2026.1724521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.03.2026. Verfasst von Dmitriy V Ivashchenko und 12 weiteren Autor:innen. Beteiligte Einrichtung: Federal State Budgetary Research Institution Russian Research Center of Surgery Named After Academician B.V. Petrovsky, Moscow, Russia. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To evaluate the associations of clinical and pharmacogenetic factors (CYP2C19*2, *17 polymorphisms) with the safety parameters of sertraline in adolescents with a depressive episode and suicidal intentions for 3 weeks in a psychiatric hospital.
Methods
The study included 112 adolescents, who were hospitalized due to a depressive episode and suicidal intentions. All patients received sertraline for 21 days. The safety of pharmacotherapy was assessed on the 7th and 21st day using the Antidepressant ADRs checklist. Each patient underwent genetic testing for CYP2C19*2, *3, *17 . The safety of sertraline was analyzed depending on the carrier status of CYP2C19 polymorphisms, the type of CYP2C19 metabolism, as well as depending on additional pharmacotherapy.
Results
It was found that patients with the CYP2C19*2 genotype took a slightly lower dose of sertraline compared to those with the wild-type genotype on 21st day (100 [87.5; 100] mg/day vs. 100 [100; 100], p = 0.048). Patients carrying the CYP2C19*17 allele, on the other hand, were more likely to experience vegetative and somatic ADRs on day 7 of treatment (2 vs. 1, p = 0.042). The use of anxiolytics (alimemazine and hydroxyzine) was significantly associated with an increased number of vegetative/somatic, and mental ADRs on day 7, as well as an increased total number of ADRs by day 21. Linear regression analysis confirmed that anxiolytics were the most significant predictors of ADR development on day 21 (Estimate = 0.86, 95% CI 0.32-1.41, p = 0.002).
Conclusion
Polypharmacy (particularly, adding a non-benzodiazepine anxiolytic) was a more significant risk factor for ADRs when taking sertraline, compared to the carrier status of CYP2C19 gene polymorphisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Federal State Budgetary Research Institution Russian Research Center of Surgery Named After Academician B.V. Petrovsky, Moscow, Russia.
- Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
- Scientific-Practical Children's and Adolescents Mental Health Center n.a. G.E. Sukhareva, Moscow, Russia.
Zitieren
APA
Ivashchenko, D. V., Sobur, V. V., Grass, S. V., Basova, A. Y., Kondratieva, R. V., Shagovenko, E. N., Chernetsova, Y. V., Tuchkova, S. N., Korsakov, I. N., Markov, S. I., Mirzaev, K. B., Shevchenko, Y. S., & Sychev, D. (2026). Sertraline safety in adolescents experiencing a depressive episode during first 3 weeks: added anxiolytic matters more than CYP2C19 polymorphisms. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1724521
Vancouver
Ivashchenko DV, Sobur VV, Grass SV, Basova AY, Kondratieva RV, Shagovenko EN, et al. Sertraline safety in adolescents experiencing a depressive episode during first 3 weeks: added anxiolytic matters more than CYP2C19 polymorphisms. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1724521
BibTeX
@article{Ivashchenko2026,
author = {Ivashchenko, Dmitriy V and Sobur, Vitaliy V and Grass, Sergey V and Basova, Anna Y and Kondratieva, Rimma V and Shagovenko, Eugenia N and Chernetsova, Yulia V and Tuchkova, Svetlana N and Korsakov, Ivan N and Markov, Sergey I and Mirzaev, Karin B and Shevchenko, Yuriy S and Sychev, Dmitry},
title = {Sertraline safety in adolescents experiencing a depressive episode during first 3 weeks: added anxiolytic matters more than CYP2C19 polymorphisms},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1724521}
}
EUVIMED